<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893382</url>
  </required_header>
  <id_info>
    <org_study_id>20.443</org_study_id>
    <nct_id>NCT04893382</nct_id>
  </id_info>
  <brief_title>Inflammatory Consequences of Crystalloids in Severely Burned Patients</brief_title>
  <official_title>Deciphering the Inflammatory Consequences of Crystalloids Used in the Resuscitation of Severely Burned Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study, but the investigators will also observe key immunological events with&#xD;
      potential significance. The global objective is to study the inflammatory profiles of&#xD;
      PlasmaLyte and Ringer's Lactate used in the initial massive fluid resuscitation of severely&#xD;
      burned patients. On the long term, the investigators will identify the crystalloid that&#xD;
      prevents hyperactivation of macrophages and death of severely burned patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have 4 specific objectives. First, the investigators will compare the&#xD;
      activation profiles of macrophages and neutrophils in patients admitted to the severely&#xD;
      burned unit with regards to the crystalloids used. Secondly, the investigators will assess&#xD;
      the differences in the SOFA scores according to the crystalloids used. Thirdly, the&#xD;
      investigators will evaluate the impact of crystalloids in the quality of skin grafts&#xD;
      performed on severely burned patients. Lastly, with the help of a patient partner, the&#xD;
      investigators will determine the right immunological terminology of the study for a&#xD;
      non-scientific population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients admitted to the severely burned unit will be randomized by the research nurse to either received PlasmaLyte or Ringer's Lactate. Research Nurse will then advise the treating team.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in monocyte phenotype from admission to day 10</measure>
    <time_frame>Pre-infusion to day 10 post-infusion</time_frame>
    <description>Following blood draws, monocytes will be subjected to flow cytometry for phenotype evaluation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>PlasmaLyte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Seven (7) severely burned patients will be infused with PlasmaLyte (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ringer's Lactate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Seven (7) severely burned patients will be infused with Ringer's Lactate (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PlasmaLyte for fluid resuscitation</intervention_name>
    <description>Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).</description>
    <arm_group_label>PlasmaLyte</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ringer's Lactate for fluid resuscitation</intervention_name>
    <description>Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).</description>
    <arm_group_label>Ringer's Lactate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  admission to the CHUM&#xD;
&#xD;
          -  more than 20% of burned area&#xD;
&#xD;
          -  first blood withdrawal in the first 24 hours following burn&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  immunosuppression&#xD;
&#xD;
          -  chemotherapy 6 months before admission&#xD;
&#xD;
          -  radiotherapy 6 months before admission&#xD;
&#xD;
          -  autoimmune diseases&#xD;
&#xD;
          -  neoplasia&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  severe infections&#xD;
&#xD;
          -  cardiac dysfunctions&#xD;
&#xD;
          -  renal dysfunction&#xD;
&#xD;
          -  hepatic dysfunctions&#xD;
&#xD;
          -  Hepatitis C&#xD;
&#xD;
          -  HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-François Cailhier, MD</last_name>
    <phone>514-890-8000</phone>
    <phone_ext>25971</phone_ext>
    <email>jf.cailhier@umontreal.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHUM</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>h2X0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Cailhier, MD</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>25971</phone_ext>
      <email>jf.cailhier@umontreal.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resuscitation</keyword>
  <keyword>Crystalloids</keyword>
  <keyword>Inflammation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

